期刊文献+

孕酮对白血病细胞的抑制增殖和诱导分化作用

Antiproliferation and Differentiation-inducing Effects of Progesterone on Leukemia Cells
下载PDF
导出
摘要 目的探讨孕酮对K562和NB4白血病细胞系的抑制增殖和诱导分化作用。方法采用细胞计数,XTT实验观察孕酮对白血病细胞增殖能力的影响,采用Wright-Giemsa染色,联苯胺染色,NBT还原实验和流式细胞术观察孕酮对白血病细胞的诱导分化作用。结果不同浓度孕酮连续作用白血病细胞5天,液体培养显示细胞数明显减少,第5天处理组的XTT值显著低于对照组,并呈剂量依赖关系;液体培养和XTT均显示孕酮对NB4细胞的增殖并无显著影响。K562细胞联苯胺染色OD值显著升高,与对照组比较差异有统计学意义(P<0.01),NB4细胞NBT还原能力提高(P<0.01),并呈剂量依赖性。形态学观察孕酮可诱导K562细胞和NB4细胞趋向成熟分化,流式细胞术检测孕酮处理后K562和NB4细胞膜CD71和CD11b分化抗原表达阳性率分别为85.72%和61.28%。结论孕酮可显著抑制K562白血病细胞增殖,诱导K562和NB4白血病细胞向成熟分化。 Objective To investigate the antiproliferation and differentiation-inducing effects of progesterone on K562 and NB4 leukemia cell line.Methods The antiproliferative effects of progesterone on leukemia cells were studied by cell count and XTT assay.The differentiation was analyzed by morphology,benzidine stain,NBT assay and flow cytometry.Results The growth of K562 cells was inhibited after treatment with progesterone for 5 days in cell count and XTT assay.But the NB4 cells inhibition rates in cell count and XTT assay was not significantly different after treatment with progesterone for 5 days.The morphology obxervation showed the differentiation tendency of K562 and NB4 cells treated with progesterone.It was also verified by bezindine stain that progesterone also induced K562 cells toward erythroid differentiation.In NBT assay,NB4 cells showed the tendency toward myelocyte differentiation.Data from flow cytometry showed that after treatment with 10-5mol/L progesterone for 4 days,the percentage of positive CD71 expression in differentiated K562 cells and positive CD11b expression in differentiated NB4 cells was 85.72% and 61.28%.Conclusion Progesterone could inhibit the proliferation of K562 cell lines and induce K562 and NB4 cells toward maturation differentiation.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2011年第6期632-635,共4页 Cancer Research on Prevention and Treatment
基金 河南省教育厅自然科学研究计划资助项目(2010B330002 2010B320011)
关键词 孕酮 K562细胞 NB4细胞 增殖 分化 Progesterone K562 cells NB4 Proliferation Differentiation
  • 相关文献

参考文献9

  • 1Chittaranjan S, McConechy M, Hou YC, et al. Steroid hor- mone control of celldeath and cell survival: molecular insights using RNAi[J]. PLoS Genet,2009,5(2) : e1000379. 被引量:1
  • 2Le Romancer M, Treilleux I, Bouehekioua-Bouzaghou K, et al. Methylation, a key step for nongenomic estrogen signaling in breast tumors[J]. Steroids, 2010,75 (8-9) : 560-564. 被引量:1
  • 3张红雨,管忠震,黄岩,张星,林桐榆.Rituximab对紫杉醇诱导人B淋巴瘤细胞株凋亡的增敏作用[J].肿瘤防治研究,2008,35(12):849-853. 被引量:2
  • 4Claus EB, Park PJ, Carroll R, et al. Specific genes expressed in association with progesterone receptors in meningioma [J]. Cancer Res,2008,68(1) :314-322. 被引量:1
  • 5Kalayarasan R, Ananthakrishnan N, Kate V, et al. Estrogen and progesterone receptors in esophageal carcinoma [J]. Dis Esophagus, 2008,21 (4) : 298-303. 被引量:1
  • 6Schindler AE. Long-term use of progestogens: colon adenoma and colon carcinoma [J]. Gynecol Endocrinol, 2007,23 (Suppl 1 ) ; 42-44. 被引量:1
  • 7Srivastava MD, Anderson DJ. Progesterone receptor expres- sion by human leukocyte cell lines; molecular mechanisms of cytokine suppression[J]. Clin Exp Obstet Gynecol, 2007, 34 (1) :14-24. 被引量:1
  • 8Samudio I, Konopleva M, Safe S, et al. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identi- fication of isomer-specific antileukemic activities of the pregna- dienedione structure[J]. Mol Cancer Ther, 2005,4(12) : 1982- 1992. 被引量:1
  • 9Suzuki T, Murry BA, Darnel AD, et al. Progesterone metabo- lism in human leukemic monoblast U937 cells[J]. Endocr J, 2002,49(5) :539-546. 被引量:1

二级参考文献15

  • 1Fisher RI, Gaynor ER, Dahlberg S, et al. A phase Ⅲ comparison of CHOP vs. m BACOD vs. Pro MACE Cyta BOM vs MACOP-B in patients with intermediate-or high-grade non- Hodgkin’s lymphoma; results of SWOG-8516 (Intergroup 0067), the National High Priority Lymphoma study [J]. Ann Oneol, 1994,5 (Suppl 2) :91-95. 被引量:1
  • 2Vose JM, Link BK,Grossbard ML, et al. Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma [J]. J Clin Oncol,2001,19(2) :389-397. 被引量:1
  • 3Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC- C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J]. Cancer Biother Ra diopharm, 1997,12(3) : 177-186. 被引量:1
  • 4Shan D, Ledbetter JA,Press OW. Apoptosis of malignant hu man B cells by ligation of CD20 with monoelonal antibodies [J]. Blood, 1998,91 (5) : 1644-1652. 被引量:1
  • 5Long HJ. Paelitaxel (Paclitaxel) : a novel anticancer chemotherapeutic drug[J]. Mayo Clin Proc, 1994,69(4) :3412-3415. 被引量:1
  • 6Emmanouilides C,Jazirehi AR, Bonavida B. Rituximab-media-ted sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine [J]. Cancer Biother Radiopharm,2002, 17(6) : 621-630. 被引量:1
  • 7Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma[J].Blood, 1997,90(6) :2188-2195. 被引量:1
  • 8Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combina tion with CHOP or fludarabine in low-grade lymphoma[J].Semin Oncol,2002,29(1 Suppl 2):36-40. 被引量:1
  • 9Vose JM,Link BK,Grossbard ML,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma [J].J Clin Oncol,2001,19(2) :389-397. 被引量:1
  • 10Reff ME,Carner K,Chambers KS,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83 (2) : 435-445. 被引量:1

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部